MedTrace Logo

A Long-term Follow-up Study of Patients With ARD103 CAR-T Cell Therapies

NCT06906380 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 49

Last updated 2025-12-08

No results posted yet for this study

Summary

This study will evaluate the long-term safety of ARD103 cellular therapies

Conditions

  • Acute Myeloid Leukemia, in Relapse
  • Acute Myeloid Leukemia, in Relapsed or Refractory
  • MDS (Myelodysplastic Syndrome)

Interventions

OTHER

Non interventional study

Non Intervention, an observation LTFU study

Sponsors & Collaborators

  • ARCE Therapeutics, Inc.

    lead INDUSTRY

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-15
Primary Completion
2040-05-30
Completion
2040-10-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06906380 on ClinicalTrials.gov